References
1. Arock M, Sotlar K, Gotlib J, Sperr WR, Hartmann K, Schwartz LB, et
al. New developments in the field of mastocytosis and mast cell
activation syndromes: a summary of the Annual Meeting of the European
Competence Network on Mastocytosis (ECNM) 2019. Leuk Lymphoma .
2020;61(5):1075-83.
2. Reiter A, George TI, Gotlib J. New developments in diagnosis,
prognostication, and treatment of advanced systemic mastocytosis.Blood . 2020;135(16):1365-76.
3. Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO
classification and novel emerging treatment concepts. Blood .
2017;129(11):1420-7.
4. Kunder CA, St John AL, Abraham SN. Mast cell modulation of the
vascular and lymphatic endothelium. Blood . 2011;118(20):5383-93.
5. Bucci T, Parente R, De Feo G, Cardamone C, Triggiani M. Flow-mediated
dilation shows impaired endothelial function in patients with
mastocytosis. J Allergy Clin Immunol . 2019;144(4):1106-11.
6. Godo S, Shimokawa H. Endothelial Functions. Arterioscler Thromb
Vasc Biol . 2017;37(9):e108-e14.
7. Leite AR, Borges-Canha M, Cardoso R, Neves JS, Castro-Ferreira R,
Leite-Moreira A. Novel Biomarkers for Evaluation of Endothelial
Dysfunction. Angiology . 2020;71(5):397-410.
8. Poggesi A, Pasi M, Pescini F, Pantoni L, Inzitari D. Circulating
biologic markers of endothelial dysfunction in cerebral small vessel
disease: A review. J Cereb Blood Flow Metab . 2016;36(1):72-94.
9. Dobbie LJ, Mackin ST, Hogarth K, Lonergan F, Kannenkeril D,
Brooksbank K, et al. Validation of semi-automated flow-mediated dilation
measurement in healthy volunteers. Blood Press Monit .
2020;25(4):216-23.
10. Stout M. Flow-mediated dilatation: a review of techniques and
applications. Echocardiography . 2009;26(7):832-41.
11. Demirturk M, Akpinar TS, Kose M, Gelincik A, Colakoglu B,
Buyukozturk S. Endocan: A Novel Marker of Endothelial Dysfunction in
C1-Inhibitor-Deficient Hereditary Angioedema. Int Arch Allergy
Immunol . 2017;174(2):104-7.
12. Kliche S, Waltenberger J. VEGF receptor signaling and endothelial
function. IUBMB Life . 2001;52(1-2):61-6.
13. Dambala K, Paschou SA, Michopoulos A, Siasos G, Goulis DG, Vavilis
D, et al. Biomarkers of Endothelial Dysfunction in Women With Polycystic
Ovary Syndrome. Angiology . 2019;70(9):797-801.
14. Kowalczyk A, Kleniewska P, Kolodziejczyk M, Skibska B, Goraca A. The
role of endothelin-1 and endothelin receptor antagonists in inflammatory
response and sepsis. Arch Immunol Ther Exp (Warsz) .
2015;63(1):41-52.
15. Lankhorst S, Danser AH, van den Meiracker AH. Endothelin-1 and
antiangiogenesis. Am J Physiol Regul Integr Comp Physiol .
2016;310(3):R230-4.
16. Vanhoutte PM, Shimokawa H, Feletou M, Tang EH. Endothelial
dysfunction and vascular disease - a 30th anniversary update. Acta
Physiol (Oxf) . 2017;219(1):22-96.
17. Valent P. KIT D816V and the cytokine storm in mastocytosis:
production and role of interleukin-6. Haematologica .
2020;105(1):5-6.
18. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of
C-reactive protein and low-density lipoprotein cholesterol levels in the
prediction of first cardiovascular events. N Engl J Med .
2002;347(20):1557-65.
19. Sun J, Sukhova GK, Wolters PJ, Yang M, Kitamoto S, Libby P, et al.
Mast cells promote atherosclerosis by releasing proinflammatory
cytokines. Nat Med . 2007;13(6):719-24.
20. Kritikou E, Depuydt MAC, de Vries MR, Mulder KE, Govaert AM, Smit
MD, et al. Flow Cytometry-Based Characterization of Mast Cells in Human
Atherosclerosis. Cells . 2019;8(4).
21. Bots ML, Evans GW, Tegeler CH, Meijer R. Carotid Intima-media
Thickness Measurements: Relations with Atherosclerosis, Risk of
Cardiovascular Disease and Application in Randomized Controlled Trials.Chin Med J (Engl) . 2016;129(2):215-26.
22. Nezu T, Hosomi N, Aoki S, Matsumoto M. Carotid Intima-Media
Thickness for Atherosclerosis. J Atheroscler Thromb .
2016;23(1):18-31.
23. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka
PA, et al. Recommendations for chamber quantification: a report from the
American Society of Echocardiography’s Guidelines and Standards
Committee and the Chamber Quantification Writing Group, developed in
conjunction with the European Association of Echocardiography, a branch
of the European Society of Cardiology. J Am Soc Echocardiogr .
2005;18(12):1440-63.
24. Yeboah J, Crouse JR, Hsu FC, Burke GL, Herrington DM. Brachial
flow-mediated dilation predicts incident cardiovascular events in older
adults: the Cardiovascular Health Study. Circulation .
2007;115(18):2390-7.
25. Yeboah J, Folsom AR, Burke GL, Johnson C, Polak JF, Post W, et al.
Predictive value of brachial flow-mediated dilation for incident
cardiovascular events in a population-based study: the multi-ethnic
study of atherosclerosis. Circulation . 2009;120(6):502-9.
26. Stein JH. Carotid intima-media thickness and vascular age: you are
only as old as your arteries look. J Am Soc Echocardiogr .
2004;17(6):686-9.
27. Gangemi S, Minciullo PL, Magliacane D, Saitta S, Loffredo S, Saija
A, et al. Oxidative stress markers are increased in patients with
mastocytosis. Allergy . 2015;70(4):436-42.
28. Brockow K. Epidemiology, prognosis, and risk factors in
mastocytosis. Immunol Allergy Clin North Am . 2014;34(2):283-95.
29. Valent P. Mastocytosis: a paradigmatic example of a rare disease
with complex biology and pathology. Am J Cancer Res .
2013;3(2):159-72.
30. Indhirajanti S, van Daele PLA, Bos S, Mulder MT, Bot I, Roeters van
Lennep JE. Systemic mastocytosis associates with cardiovascular events
despite lower plasma lipid levels. Atherosclerosis .
2018;268:152-6.
31. Unal D, Gelincik A, Elitok A, Demir S, Olgac M, Coskun R, et al.
Impact of high serum Immunoglobulin E levels on the risk of
atherosclerosis in humans. Asia Pac Allergy . 2017;7(2):74-81.
32. Melincovici CS, Bosca AB, Susman S, Marginean M, Mihu C, Istrate M,
et al. Vascular endothelial growth factor (VEGF) - key factor in normal
and pathological angiogenesis. Rom J Morphol Embryol .
2018;59(2):455-67.
33. Possomato-Vieira JS, Khalil RA. Mechanisms of Endothelial
Dysfunction in Hypertensive Pregnancy and Preeclampsia. Adv
Pharmacol . 2016;77:361-431.
34. Boesiger. Mast Cells Can Secrete Vascular Permeability Factor/
Vascular Endothelial Cell Growth Factor and Exhibit Enhanced Release
after Immunology E–dependent Up regulation of Fce Receptor I
Expression. J Exp Med . 1998;188:1135–45.
35. Wimazal F, Jordan JH, Sperr WR, Chott A, Dabbass S, Lechner K, et
al. Increased angiogenesis in the bone marrow of patients with systemic
mastocytosis. Am J Pathol . 2002;160(5):1639-45.
36. Gunay M, Mertoglu C. Increase of endocan, a new marker for
inflammation and endothelial dysfunction, in acute kidney injury.North Clin Istanb . 2019;6(2):124-8.
37. Kanbay A, Ceylan E, Koseoglu HI, Caliskan M, Takir M, Tulu S, et al.
Endocan: a novel predictor of endothelial dysfunction in obstructive
sleep apnea syndrome. Clin Respir J . 2018;12(1):84-90.
38. Musialowska D, Zbroch E, Koc-Zorawska E, Musialowski P, Malyszko J.
Endocan Concentration in Patients With Primary Hypertension.Angiology . 2018;69(6):483-9.
39. Wang J, Yu W, Gao M, Zhang F, Gu C, Yu Y, et al. Impact of
Obstructive Sleep Apnea Syndrome on Endothelial Function, Arterial
Stiffening, and Serum Inflammatory Markers: An Updated Meta-analysis and
Metaregression of 18 Studies. J Am Heart Assoc . 2015;4(11).
40. Lee W, Ku SK, Kim SW, Bae JS. Endocan elicits severe vascular
inflammatory responses in vitro and in vivo. J Cell Physiol .
2014;229(5):620-30.
41. Idris-Khodja N, Ouerd S, Mian MOR, Gornitsky J, Barhoumi T, Paradis
P, et al. Endothelin-1 Overexpression Exaggerates Diabetes-Induced
Endothelial Dysfunction by Altering Oxidative Stress. Am J
Hypertens . 2016;29(11):1245-51.
42. Brockow K, Akin C, Huber M, Metcalfe DD. IL-6 levels predict disease
variant and extent of organ involvement in patients with mastocytosis.Clin Immunol . 2005;115(2):216-23.